Novogen (ASX:NRT; NASDAQ:NVGN) will strengthen its intellectual property position on its key anti-tropomyosin technology platform, lodging two new patents.
Novogen has two drug technology platforms, the Superbenzopyran (SBP) and anti-tropomyosin (ATM) with established patent positions.
Acting CEO Iain Ross, said the company currently had an extensive program of activities underway including the lead pre-clinical programs and discovery programs.
The medicinal chemistry programs have identified two promising drug candidates (Cantrixil and Anisina), which Novogen is progressing down the translational development path.
Novogen is searching for a world class CEO and to beef up its project and manufacturing management support ranks.
The company held $45 million in cash in June.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.